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Abstract
Purpose Potentially inappropriate prescriptions (PIPs) criteria
are widely used for evaluating the quality of prescribing in
elderly. However, there is limited evidence on their associa-
tion with adverse drug reactions (ADRs) across healthcare
settings. The study aimed to determine the prevalence of PIPs,
defined by the Screening Tool of Older Persons’ potentially
inappropriate Prescriptions (STOPP) criteria, in the Swedish
elderly general population and to investigate the association
between PIPs and occurrence of ADRs.
Method Persons ≥65 years old were identified from a random
sample of 5025 adults drawn from the Swedish Total Popula-
tion Register. A retrospective cohort study was conducted
among 813 elderly with healthcare encounters in primary
and specialised healthcare settings during a 3-month period
in 2008. PIPs were identified from the Swedish Prescribed
Drug Register, medical records and health administrative data.
ADRs were independently identified by expert reviewers in a
stepwise manner using the Howard criteria. Multivariable lo-
gistic regression examined the association between PIPs and
ADRs.
Results Overall, 374 (46.0 %) persons had ≥1 PIPs and 159
(19.5 %) experienced ≥1 ADRs during the study period. In
total, 29.8 % of all ADRs was considered caused by PIPs.
Persons prescribed with PIPs had more than twofold increased
odds of experiencing ADRs (OR 2.47; 95 % CI 1.65–3.69).
PIPs were considered the cause of 60% of ADRs affecting the
vascular system, 50 % of ADRs affecting the nervous system
and 62.5 % of ADRs resulting in falls.
Conclusion PIPs are common among the Swedish elderly and
are associated with increased odds of experiencing ADRs.
Thus, interventions to decrease PIPs may contribute to
preventing ADRs, in particular ADRs associated with nervous
and vascular disorders and falls.
Keywords Inappropriate prescribing . Elderly . Adverse drug
reactions . Retrospective study .Medical records . Registries
Background
The rapid growth in the proportion of older population in-
creases demands on healthcare systems worldwide [1]. Sever-
al factors contribute to the challenge of the care of the elderly,
including comorbidities and chronic conditions often requir-
ing multiple medications [2, 3], age-related physiological
changes leading to increased sensitivity to drug effects [4]
and limited evidence of drug effectiveness and safety in older
and frail patients [5]. Previous studies have reported that up to
61 % of older patients in hospital settings develop adverse
drug reactions (ADRs) [6], and approximately half of them
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are potentially preventable [7]. Potentially inappropriate pre-
scriptions (PIPs) may be defined as Bthe prescriptions that
introduce a significant risk of an adverse drug related event
when there is evidence for an equally or more effective alter-
native medication^ [8]. PIPs have been reported as an impor-
tant cause of iatrogenic morbidity [9], mortality [10] and in-
creased healthcare costs [11].
Explicit prescribing criteria have been developed to raise
prescribers’ and other healthcare providers’ awareness about
inappropriate prescribing and to improve the quality of pre-
scribing in the elderly [12, 13]. The Screening Tool of Older
Persons’ potentially inappropriate Prescriptions (STOPP),
published in 2008 [14], has been endorsed by researchers in
different jurisdictions, in Europe and elsewhere, for evaluating
the quality of prescribing of elderly patients with multiple
chronic conditions [15–18]. However, evidence of an associ-
ation between PIPs identified by STOPP criteria and the oc-
currence of ADRs is limited [19] and mainly studied in hos-
pital settings [20–22]. As the majority of healthcare contacts
of the elderly occur in primary care [23], we aimed to deter-
mine the prevalence of PIPs, defined by STOPP criteria, in the
Swedish elderly general population, including all care set-
tings, and to study the association between PIPs and occur-
rence of ADRs.
Methods
Study design and study population
Individuals older than 65 years were identified from a random
sample of 5025 adult residents in the County Council of
Östergötland, drawn from the Total Population Register of
Statistics Sweden [24]. A retrospective cohort study was con-
ducted using the medical data of older patients, who had at
least one healthcare encounter in primary or specialised care
over a 3-month period in 2008.
Data sources
Several data sources were linked using the personal identity
number [25]. Data on prescribed medications were extracted
from the Swedish Prescribed Drug Register (SPDR) [26]. The
register includes dispensed prescribed drugs for outpatients,
residential care and nursing homes, but excludes drugs admin-
istered in hospitals, and emergency drugs in residential care
and nursing homes. Data on healthcare encounters were re-
trieved from the regional patient register (the Care Data Ware-
house of Östergötland County), which includes administrative
data on all inpatient and outpatient care provided in the county
in all medical specialties and its coverage is considered full
[27]. Based on the administrative care data, electronic medical
records in all care units were reviewed during the study




The STOPP criteria include 65 instances of common PIPs,
including drug-drug and drug-disease interactions, unneces-
sary therapeutic duplication and drugs which can increase
the risks of cognitive decline and falls in older patients [14].
Patient medical data, including medical histories, diagnoses
and current medications, were recorded by one research phar-
macist. Prescribed medications were identified from the
SPDR through the Anatomical Therapeutic Chemical (ATC)
classification system. PIPs were assessed during 6 months,
including 3 months prior the study period. The research phar-
macist referred to the research team in the event of uncertainty
regarding interpretation of the clinical data and application of
the STOPP criteria.
Detection of ADRs
An ADR was defined according to the World Health Organi-
sation as Ba response to a drug which is noxious and unintend-
ed, and which occurs at doses normally used in man…^ [28].
ADRs were detected in a stepwise manner. All suspected
ADRs occurring during the study period were initially
analysed by other research pharmacists than the one who iden-
tified PIPs. They extracted information from the medical re-
cords for the 3-month study period, 9 months before and
3 months after. Used triggers included symptoms indicating
worsening health status [29], common drug/adverse event
combinations [29] and drug-drug interactions [30]. A clinical
pharmacologist and a senior pharmacist independently
assessed the causality between the prescribed medications
and the suspected ADRs using Howard algorithm [31]. Con-
flicting assessments were solved by consensus. Suspected
ADRs with at least possible causality were considered ADRs.
The seriousness of ADRs was assessed [32]. Finally, PIPs
with causal contribution to the identified ADRs were
considered.
Statistical analysis
The baseline characteristics of the study population included
the number of prescribed medications, the level of healthcare
use (defined by Diagnosis Related Group (DRG) weights
[33]) 3 months prior to the study period and the most common
morbidities. We estimated the prevalence of individuals with
at least one PIP, with elderly individuals who had a healthcare
encounter during the study period as the denominator. The
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most common PIPs (those occurring in at least ten individuals)
and the proportion causing ADRs was reported.
The 3-month prevalence of individuals with ADRs and the
proportion of ADRs considered as caused by PIPs were cal-
culated. The ten most common organ system disorders and
symptoms, as defined by the Medical Dictionary for Regula-
tory Activities (MedDRA) [34], were reported, and the pro-
portion considered as caused by PIPs was calculated. Serious
ADRs judged to be caused by PIPs were described.
The association between PIPs and ADRs was investigated
with a multivariable logistic regression. The results were ad-
justed for age (65–74, 75–84, ≥85 years), sex, number of
dispensed prescribed medications (0, 1, 2–5, 6–9, ≥10), level
of healthcare use and use of multidose drug dispensing [35].
Data analysis was performed using Stata version 11.1
(StataCorp, TX). P value of less than 0.05 was considered
statistically significant.
Finally, a sensitivity analysis was performed without the 12
criteria that are excluded from the updated STOPP version
(November 2014) [36].
Ethical consideration
The study was approved by the Regional Ethical Review
Board in Gothenburg (no: 644-2008) according to the Swed-
ish regulation. Informed consent of participants was not re-
quired as the retrospective study design did not affect the
healthcare of included patients. Statistics Sweden replaced
the personal identity numbers by a random serial number after
the final data linkage and data were analysed anonymously.
Results
Data were collected from 813 elderly. The main characteristics
of the study population are summarised in Table 1. The medi-
an age was 75.0 years (range 65–98 years). In total, 66.7 %
had encounters exclusively in primary care, and 7.3 % was
hospitalised 3 months prior to the study period. Overall,
25.2 % of the study population was prescribed 6 to 9 medica-
tions and 12.0 % ≥10 medications.
We found 607 PIPs prescribed to 374 persons (46.0 %)
(Table 2). The prevalence of PIPs was 42.8 % among those
with exclusively primary healthcare contacts, 52.4 % among
those with specialised healthcare and 66.1 % among the elder-
ly who were hospitalised at least once during the 3-month
study period. Multivariable regression analysis showed that
persons prescribed PIPs hadmore than twofold increased odds
to experience ADRs (odds ratio (OR) 2.47, 95 % confidence
interval (CI) 1.65–3.69); p<0.001), compared to that in per-
sons without PIPs.
The most common PIPs are described in Table 3. In total,
10.5 % of PIPs caused ADRs (Table 3). The percentage of
PIPs considered causing ADRs was the highest for vasodila-
tors in persons with persistent postural hypotension (92.3 % of
PIPs causing ADRs), prolonged use of neuroleptics (46.2 %),
first-generation antihistamines (25.0 %) and benzodiazepines
(23.3 %) in those prone to fall.
Overall, 245 ADRs were identified in 159 persons
(19.6 %), of which 73 were considered as caused by PIPs
(29.8 % of all ADRs). PIPs were considered the cause of a
high percentage of ADRs affecting the vascular and nervous
systems (60.0 and 50.0 %, respectively) (Fig. 1). Moreover,
62.5 % of ADRs resulting in falls were considered as caused
by inappropriate use of benzodiazepines (Fig. 2).
Twelve serious ADRs were identified; among them, eight
were considered caused by PIPs mainly by antipsychotic and
Table 1 Study population characteristics (n=813)
Characteristics n (%)
Age (years)













Patients prescribed cardiovascular medicationsb 595 (73.2)
Patients prescribed psychotropic medicationsc 278 (34.2)
Use of multiple drug dispensing 85 (10.4)
Level of healthcare used
Primary care 542 (66.7)





Ischemic heart disease 147 (18.1)
Mental and behavioural disorders 140 (17.2)
Heart failure 85 (10.5)
Osteoarthritis 83 (10.2)
Chronic obstructive pulmonary disease 68 (8.4)
Dementia 28 (3.4)
a Three months prior to the study period
bAnatomical Therapeutic Chemical code C
cAnatomical Therapeutic Chemical code N05 and N06
dDefined by DRG weights
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non-steroidal anti-inflammatory drugs (Supplement 1). One
death was judged to be caused by the long-term use of
nitrazepam.
Sensitivity analysis
When the analyses were limited to the 53 criteria included in the
updated STOPP version [36], 270 (33.2 %) elderly persons had
at least one PIP, 24.9 % of ADRs were considered as caused by
PIPs, and PIPs were significantly associated with the occur-
rence of ADRs (OR 2.57, 95 % CI 1.75–3.77, p<0.001).
Discussion
Nearly half of patients across care settings were prescribed
with one or more PIPs during a 3-month period. Moreover,
one third of ADRs were considered caused by PIPs, and el-
derly who were prescribed with PIPs had over twofold in-
creased odds to experience ADRs.
Our findings indicate that PIPs are common among patients
in both primary and specialised healthcare. The prevalence of
PIPs in studies using the STOPP criteria has ranged between
21 and 79 %, depending on the study setting and design [19].
In accordance with a Spanish study [37], our PIP prevalence
was higher in specialised care compared to that in primary
care. Persons using more advanced care probably have more
complex comorbidities, which have been associated with PIPs
[38]. However, elderly in specialised care may not be repre-
sentative of the elderly population as a whole. As the majority
of elderly use mainly primary care, the understanding of PIPs
in primary care must be improved. Furthermore, the validity
of detecting PIPs among the elderly in the general population
should be investigated.
The most frequent PIPs in our study partially differed from
common PIPs in hospital-based studies [19, 20, 39, 40]. Sim-
ilarly to studies conducted in hospital settings [19], the long-
term use of long-acting benzodiazepines and medications in-
creasing the risk of fall (such as benzodiazepines, opiates and
first-generation antihistamines) were among the most
Table 3 Most common potentially inappropriate prescriptions
Criterion n (%) n (%) causing
ADRs
Aspirin with no history of coronary, cerebral or peripheral arterial symptoms or occlusive arterial event 154 (18.9) 7 (6.5)
Benzodiazepines in those prone to fall 43 (5.4) 10 (23.3)
NSAID with moderate-severe hypertension 41 (5.0) 1 (2.4)
Long-term long-acting benzodiazepines 37 (4.6) 3 (8.1)
Prolonged use (>1 week) of first generation antihistamines 28 (3.4) 7 (25.0)
Use of long-term powerful opiates as first-line therapy for mild-moderate pain 27 (3.3) 0 (0)
Long-term opiates in those with recurrent falls 26 (3.2) 6 (23.1)
Long-term (i.e. >1 month) neuroleptics as long-term hypnotics 26 (3.2) 12 (46.2)
Oestrogens without progestogen in patients with intact uterus 23 (2.8) 0 (0)
Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthritis or osteoarthritis 19 (2.3) 2 (10.5)
Aspirin at dose >150 mg/day 17 (2.1) 0
Long-term use of NSAID (>3 months) for relief of mild joint pain in osteoarthritis 14 (1.7) 0
Vasodilator drugs known to cause hypotension in those with persistent postural hypotension 13 (1.6) 12 (92.3)
Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate–severe
COPD
12 (1.5) 0
First-generation antihistamines in those prone to fall 11 (1.4) 1 (9.1)
Neuroleptic drugs in those prone to fall 10 (1.2) 0
Total 607 PIPs (374
persons)
64 (10.5)
ADR adverse drug reaction, NSAID non-steroidal anti-inflammatory drugs, COPD chronic obstructive pulmonary disease
Table 2 Number of potentially inappropriate prescriptions in persons
(n=813)
Number of PIPs/person n (%)
Mean (range) 0.76 (0–9)





PIPs in persons using only primary care 226 (42.8)
PIPs in persons using specialised healthcare 148 (52.4)
PIPs in hospitalised persons 33 (66.1)
PIP potentially inappropriate prescriptions
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common PIPs in our study. However, while some PIPs, such as
proton-pump inhibitors for peptic ulcer at full therapeutic dos-
age for >8 weeks, were frequently reported among the most
common PIPs [20, 39, 40], they were rarely reported in our
study. Nonetheless, some frequently reported PIPs in our study,
such as the inappropriate prescribing of aspirin, were rarely
reported in studies conducted exclusively in hospital settings
[40]. The variation in the most common PIPs between studies
is, in addition to care settings, probably explained by differing
prescribing patterns and clinical practice guidelines, prescribing
regulation, population characteristics and disease burden
[40–42]. For example, the higher frequency of inappropriate
prescribing of aspirin in our study compared to that in previous
studiesmay be due to the commonness of aspirin as an over-the-
counter medication in other countries [43], underestimating its
inappropriate use in studies using exclusively prescription data.
We found a large part of PIPs associated with ADRs in-
volving medications that increase the risk of falls, such as
benzodiazepines, opiates and vasodilators, which indicate that
decreasing PIPs could contribute towards fall prevention.
Though falls are considered multifactorial [44], our study
found a high percentage of falls (or associated symptoms such
as dizziness and orthostatic hypotension) caused by PIPs and,
thus, considered as potentially preventable. Patients may be
unable to recognise ADRs, such as hypotension or dizziness,
or not report them to their healthcare givers, increasing the risk
of experiencing falls as ADRs, if the medication regimen is
not adjusted [45]. Medication review by prescribers and other
healthcare professionals, including a comprehensive falls as-
sessment, could decrease such PIPs, as shown by a prescribing
education programme for primary care physicians, which sig-
nificantly reduced the risk of fall among elderly patients [46].
Vasodilators appear particularly strongly associated with falls
or associated symptoms; as in our study, the percentage of
PIPs associated with ADRs was the highest for vasodilators
in those with persistent postural hypotension. Safety issues of
medications with repeat prescribing including vasodilators
have also been previously warranted [47].
Our study including all care settings found elderly with
PIPs having significantly increased odds of experiencing
ADR adverse drug reaction 
PIP potentially inappropriate prescribing 
Fig. 1 Organs affected by




ADR adverse drug reaction 
PIP potentially inappropriate prescribing 
INR international normalised ratio 
Fig. 2 The most common
symptoms of adverse drug
reactions and the proportion
caused by potentially
inappropriate prescriptions
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ADRs, demonstrating that PIPs cause potentially preventable
morbidity across care settings. Most ADRs due to PIPs in our
study were non-serious, while some previous studies have
mainly focused on the associations between PIPs and serious
adverse outcomes, such as hospitalisation and death [10, 48].
However, even mild ADRs are important to consider as they
are associated with lower quality of life, may increase the
visits to general practitioners and cause prescribing cascades
to treat symptoms of unrecognised ADRs [49]. Although we
identified few serious ADRs due to PIPs across care settings,
the ADRs included one fatal case due to long-term use of
long-acting benzodiazepines, highly recognised to be inappro-
priate in the elderly. This suggests that improving the quality
of prescribing could also prevent some fatal ADRs.
The association between PIPs and ADRs remained signif-
icant after limiting the analysis exclusively to the STOPP
criteria included in the updated version. Thus, excluding cer-
tain criteria in the updated version appears relevant. We
should emphasise, however, that the updated version was ex-
tended to 76 criteria, among them 23 criteria not listed in the
first version, including some general ones as BAny drug pre-
scribed without an evidence-based clinical indication or be-
yond the recommended duration^. Moreover, the new version
considers the use of benzodiazepines for more than 4 weeks as
inappropriate, which was found in 23.2 % of our study popu-
lation. Therefore, our estimation of PIPs prevalence may not
be an overestimation, although the most common inappropri-
ate drugs would differ between the two versions.
Strengths and limitations
Our study is the first that investigated the association between
PIPs according to STOPP criteria and ADRs among a repre-
sentative sample of the general elderly population. Neverthe-
less, our findings should be interpreted with some limitations
in mind. STOPP criteria are widely used to evaluate the qual-
ity of prescribing in the elderly. However, in some cases, med-
ications classified as potentially inappropriate may be appro-
priate considering individual patient’s health condition. Yet,
the assessment of PIPs’ causality or contribution to the detect-
ed ADR was based on a validated causality assessment algo-
rithm [31]. The SPDR includes prescriptions in outpatients
and nursing homes, and we could not include prescriptions
during hospitalisations and emergency drugs in nursing
homes and specialised care. However, only 7 % of the study
population had short hospitalisation episodes during the study
period, which also raises the question about the
generalisability of studies conducted only in hospital settings.
We were also unable to stratify our regression analysis by the
type of residence, due to unavailability of these data. Although
previous studies have found significant differences in PIPs by
type of residence [37], the potentially small number of elderly
living in nursing homes [50] would, however, limit
interpreting such stratified analysis.
The study was conducted across different healthcare orga-
nisations, with different quality and quantity of medical record
data. Some PIP criteria were impossible to evaluate in cases
with insufficient clinical information and history (e.g. infor-
mation about an intact uterus). However, our method of as-
sessment of cases, based on symptoms, biological and clinical
data, allowed the detection of ADRs that were not recognised
or reported as such in the medical records. However, symp-
toms of ADRs not communicated by patients or not recorded
by care providers in the medical records could not be detected
in this study.
While we adjusted our regression model with known fac-
tors associated with PIPs and ADRs, some confounders might
have been undetected. Further, we purposefully did not con-
sider the new criteria in the sensitivity analysis as they are
based on new recommendations that may be irrelevant to ap-
ply to prescriptions in 2008.
Implications
The STOPP criteria may be a useful tool for screening and
identifying potential ADRs in older people across healthcare
settings. While previous studies have found PIPs detected
with the STOPP criteria significantly associated with ADRs
among hospitalised patients [21], our study extend the evi-
dence on their use to detect ADRs across healthcare settings.
However, the applicability of the STOPP criteria in clinical
practice and community pharmacy needs to be established.
There is an ongoing study to integrate the STOPP criteria in
an electronic automated format [51]. Nevertheless, integrating
the STOPP criteria in the medication use reviews in commu-
nity pharmacies and general practices requires an access to
complete patient clinical data and a learning time to familiarise
with them [19].
Based on our results, the STOPP criteria seem to be partic-
ularly sensitive to detect nervous and vascular disorders and
falls. However, a better understanding of the two thirds of
ADRs due to medications not listed in the PIPs criteria, in-
cluding over-the-counter medications is needed, as they have
been associated with increased morbidity and hospitalisations
[52].
Reducing both PIPs and ADRs among the elderly will re-
quire system interventions to routinely assess drug appropri-
ateness, effectiveness, safety and adherence, while balancing
the risk of underuse of beneficial medications [53]. Moreover,
there is a need for valid patient-centred prescribing evaluation
tools across care settings to track patients’ perceived adverse
outcomes and to engage them in monitoring their medications
[53]. Improving the quality of prescribing requires a collabo-
ration of prescribers and other healthcare professionals and a
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better continuity of care of patients with chronic conditions
[54].
Conclusion
In conclusion, PIPs are common among the Swedish elderly
and are associated with twofold increased odds to experience
ADRs. The PIP criteria defined by STOPP are not a substitute
for clinical assessment and judgement, but they may encour-
age clinicians to consider medications as a possible cause of
adverse health outcomes, in particular nervous system and
vascular disorders and falls. Thus, interventions to decrease
PIPs may contribute to preventing ADRs among the elderly.
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